ASCO 2020 featured the presentation of many interesting studies in the field of lung cancer. For early stage non-small cell lung cancer (NSCLC), there was a focus on adjuvant targeted therapy while for advanced NSCLC without oncogene addiction much attention went to first-line immunotherapy and to the use of novel antibody-drug conjugates. In addition to this, several trials discussed the potential of EGFR-tyrosine kinase inhibitor (TKI) combinations, the targeting of MET alterations or RET fusions and the search for EGFR exon 20 mutant selective drugs for patients with advanced NSCLC and oncogene addictions. Finally, this overview will describe important results in the field of non-metastatic and metastatic small-cell lung cancer (SCLC) as well as advances in mesothelioma.

(BELG J MED ONCOL 2020;14(5):201-8)